Edgewise Therapeutics, Inc. (EWTX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Edgewise Therapeutics, Inc. (EWTX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Seeking Alpha • Dec 4, 2025

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

BOULDER, Colo. , Dec. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on November 28, 2025, Edgewise granted an inducement stock option to purchase a total of 26,250 shares of Edgewise's common stock to a new non-executive employee in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan").

PRNewsWire • Dec 2, 2025

Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors

BOULDER, Colo. , Nov. 20, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced the appointment of biotechnology veteran Christopher Martin to its Board of Directors.

PRNewsWire • Nov 20, 2025

Edgewise Therapeutics Announces Appointment of Michael Nofi as Chief Financial Officer, and the Retirement of Current CFO, R. Michael Carruthers

BOULDER, Colo. , Nov. 10, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced the appointment of Michael Nofi, as Chief Financial Officer (CFO), effective November 10, 2025.

PRNewsWire • Nov 10, 2025

Edgewise Therapeutics to Participate in Upcoming Investor Conferences

BOULDER, Colo. , Nov. 7, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will participate in the following investor conferences: Guggenheim 2nd Annual Healthcare Innovation Conference Fireside chat: Tuesday, November 11, 2025 at 8:30 am ET Piper Sandler 37th Annual Healthcare Conference Fireside chat: Tuesday, December 2, 2025 at 2 pm ET 8th Annual Evercore Healthcare Conference Fireside chat: Wednesday, December 3, 2025 at 3:25 pm ET The webcasts can be found on the Edgewise Events & Presentations page and will be accessible for replay, for a limited time, following the conference.

PRNewsWire • Nov 7, 2025

Edgewise Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

–  Pivotal GRAND CANYON cohort of sevasemten in Becker expected to read out in Q4 2026; building infrastructure to support potential commercial launch – –  MESA open-label extension trial of sevasemten in Becker muscular dystrophy continues to enroll nearly all eligible participants – –  Continuing to advance Phase 2 CIRRUS-HCM trial of EDG-7500 in Hypertrophic Cardiomyopathy; on track to provide program update in Q4 2025 – – Initiated Phase 1 healthy adult trial of EDG-15400 for future studies in Heart Failure – BOULDER, Colo. , Nov. 6, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the third quarter of 2025 and recent business highlights.

PRNewsWire • Nov 6, 2025

Edgewise Therapeutics to Present on Sevasemten for Becker and Duchenne Muscular Dystrophies at the 30th International Annual Congress of the World Muscle Society

BOULDER, Colo. , Oct. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced its participation at the 30th International Annual Congress of the World Muscle Society (WMS).

PRNewsWire • Oct 2, 2025

Wall Street Analysts Think Edgewise Therapeutics (EWTX) Could Surge 182%: Read This Before Placing a Bet

The mean of analysts' price targets for Edgewise Therapeutics (EWTX) points to an 182% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Investment Research • Sep 18, 2025

Wall Street Analysts Believe Edgewise Therapeutics (EWTX) Could Rally 172.96%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 173% in Edgewise Therapeutics (EWTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Investment Research • Sep 2, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX

NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Edgewise Therapeutics, Inc. (“Edgewise” or the “Company”) (NASDAQ: EWTX).  Such investors are advised to contact Danielle Peyton at  [email protected]  or 646-581-9980, ext. 7980.

GlobeNewsWire • Aug 17, 2025